08:26 AM EDT, 08/25/2025 (MT Newswires) -- Immuneering ( IMRX ) said Monday it has entered into a clinical supply agreement with Eli Lilly ( LLY ) for its second-generation KRAS G12C inhibitor, olomorasib, aimed at non-small cell lung cancer.

The company said the agreement supports evaluating atebimetinib, its lead product candidate and a novel dual MEK inhibitor that blocks proteins MEK1 and MEK2 to stop cancer growth.

It further added that atebimetinib will be tested in combination with olomorasib in a Phase 2 trial for patients with advanced KRAS G12c-mutant non-small cell lung cancer who have progressed on prior therapy.